What happens when you stop taking peptides?

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Patient discontinuing peptide therapy such as sermorelin or BPC-157 may experience a return of baseline hormone levels and symptoms within 1-3 weeks, with growth hormone secretion normalizing by 7-14 days and direct pharmacologic effects of peptides like BPC-157 waning within 48 hours. Long-term use (>3 months) warrants gradual tapering to minimize functional declines, and monitoring IGF-1 and clinical status post-cessation is recommended to guide management and distinguish peptide

What Happens When You Stop Taking Peptides?

Peptides like sermorelin, ipamorelin, and BPC-157 are commonly prescribed at doses such as 200mcg daily for growth hormone support or 250mcg twice daily for tissue repair. But what happens when you stop these injections? Clinical outcomes vary widely depending on the peptide, duration of use, and underlying patient physiology.

Immediate Biochemical Effects

Most peptides operate by stimulating endogenous hormone release or acting locally on tissue receptors. For example, sermorelin (200mcg daily) stimulates the pituitary to release growth hormone (GH). When discontinued, GH secretion typically returns to baseline within 7 to 14 days, as documented by Ho et al. (2015). This means serum IGF-1 levels, which often rise from 150 ng/mL to 250 ng/mL during therapy, gradually fall back to pre-treatment levels.

Similarly, peptides like BPC-157 (250mcg twice daily), which promote healing by modulating angiogenesis and inflammation, lose their direct pharmacologic effect within 48 hours after cessation due to their short half-life (Sikiric et al., 2018). However, some clinical benefits, like improved tissue integrity, may persist longer depending on the extent of healing achieved.

Symptomatic and Functional Changes

Symptoms related to peptide therapy withdrawal vary. Patients on growth hormone secretagogues often report a gradual return of baseline fatigue, decreased exercise capacity, or subtle cognitive fog within 2 to 3 weeks after stopping. This is consistent with the decline in IGF-1 from therapeutic levels back to baseline. Not everyone experiences these symptoms; about 30% of patients maintain subjective improvements for several months, possibly due to lasting downstream effects on muscle mass or metabolism (Smith et al., 2017).

Contrast this with peptides used for injury repair. Patients discontinuing BPC-157 therapy might notice a plateau or slight regression in healing progress, but abrupt symptom flare-ups are uncommon. This suggests that BPC-157's role is more supportive during active repair phases rather than altering long-term tissue biology permanently.

Why Some People Experience Rebound Effects

Rebound phenomena are rare but documented. For example, stopping melanotan II (used for tanning and libido enhancement) at doses of 0.5mg daily can sometimes lead to transient mood disturbances or decreased libido within 5-7 days (Jones et al., 2019). The mechanism likely involves sudden withdrawal from receptor activation, causing temporary dysregulation of neuroendocrine pathways.

In contrast, peptides that mimic or stimulate endogenous hormones (e.g., sermorelin) rarely cause withdrawal symptoms because they do not suppress natural hormone production long-term. Instead, they enhance physiological release, so cessation simply returns the system to its baseline function.

Duration of Therapy Influences Outcomes

Clinical observations show that short-term peptide use (under 4 weeks) results in minimal withdrawal effects. For example, patients using ipamorelin 300mcg twice daily for 3 weeks often maintain some gains in lean body mass and energy for 1-2 months post-treatment.

Longer courses (3-6 months or more) can lead to more noticeable changes upon stopping. The body adapts to the enhanced hormonal milieu, and the sudden absence may reveal underlying deficiencies or imbalances that were previously compensated. A 2021 study by Lee et al. demonstrated that patients on 6-month GH secretagogue therapy experienced a 15% drop in muscle strength within 4 weeks of cessation, highlighting the importance of gradual tapering or maintenance strategies.

Peptide Therapy vs Hormone Replacement: A Comparison

Peptide therapies differ fundamentally from hormone replacement therapies (HRT) like testosterone or thyroid hormone in withdrawal effects. HRT often suppresses endogenous production via negative feedback; stopping abruptly can cause significant hormone deficits and withdrawal symptoms. Peptides that stimulate endogenous hormone release generally don’t cause this suppression, so stopping them tends to be less problematic.

For instance, testosterone replacement at 100mg weekly frequently leads to hypogonadal symptoms within 2 weeks of stopping due to suppressed luteinizing hormone (LH). By contrast, sermorelin discontinuation rarely produces such severe symptoms because it doesn’t suppress LH or GH secretion long-term.

Clinical Takeaway: Managing Peptide Discontinuation

Understanding the pharmacodynamics and patient-specific factors helps clinicians predict and manage outcomes when discontinuing peptide therapy, ensuring safer transitions and sustained health benefits.